Drugs / AGN-231868
last change Mar 2022 re-read 2 minutes ago

AGN-231868

Developed for
dry eye syndrome
Investigated by
AbbVie

Trials 1 · a red edge is where a trial was stopped

2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04030962 Mar 2020 → Mar 2022 dry eye syndrome AbbVie Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AGN-231868 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04030962
Route Topical “Ophthalmic solution administered as a topical eye drop” NCT04030962